Literature DB >> 24573553

Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.

Hanwen Zhang1, Ruimin Huang, Nai-Kong V Cheung, Hongfen Guo, Pat B Zanzonico, Howard T Thaler, Jason S Lewis, Ronald G Blasberg.   

Abstract

PURPOSE: The norepinephrine transporter (NET) is a critical regulator of catecholamine uptake in normal physiology and is expressed in neuroendocrine tumors like neuroblastoma. Although the norepinephrine analog, meta-iodobenzylguanidine (MIBG), is an established substrate for NET, (123)I/(131)I-MIBG has several clinical limitations for diagnostic imaging. In the current studies, we evaluated meta-[(18)F]-fluorobenzylguanidine ([(18)F]-MFBG) and compared it with (123)I-MIBG for imaging NET-expressing neuroblastomas. EXPERIMENTAL
DESIGN: NET expression levels in neuroblastoma cell lines were determined by Western blot and (123)I-MIBG uptake assays. Five neuroblastoma cell lines and two xenografts (SK-N-BE(2)C and LAN1) expressing different levels of NET were used for comparative in vitro and in vivo uptake studies.
RESULTS: The uptake of [(18)F]-MFBG in cells was specific and proportional to the expression level of NET. Although [(18)F]-MFBG had a 3-fold lower affinity for NET and an approximately 2-fold lower cell uptake in vitro compared with that of (123)I-MIBG, the in vivo imaging and tissue radioactivity concentration measurements demonstrated higher [(18)F]-MFBG xenograft uptake and tumor-to-normal organ ratios at 1 and 4 hours after injection. A comparison of 4 hours [(18)F]-MFBG PET (positron emission tomography) imaging with 24 hours (123)I-MIBG SPECT (single-photon emission computed tomography) imaging showed an approximately 3-fold higher tumor uptake of [(18)F]-MFBG, but slightly lower tumor-to-background ratios in mice.
CONCLUSIONS: [(18)F]-MFBG is a promising radiopharmaceutical for specifically imaging NET-expressing neuroblastomas, with fast pharmacokinetics and whole-body clearance. [(18)F]-MFBG PET imaging shows higher sensitivity, better detection of small lesions with low NET expression, allows same day scintigraphy with a shorter image acquisition time, and has the potential for lower patient radiation exposure compared with (131)I/(123)I-MIBG. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573553      PMCID: PMC4072734          DOI: 10.1158/1078-0432.CCR-13-1153

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging.

Authors:  Yuan-Chuan Tai; Ananya Ruangma; Douglas Rowland; Stefan Siegel; Danny F Newport; Patrick L Chow; Richard Laforest
Journal:  J Nucl Med       Date:  2005-03       Impact factor: 10.057

2.  Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.

Authors:  Hanwen Zhang; Ruimin Huang; NagaVaraKishore Pillarsetty; Daniel L J Thorek; Ganesan Vaidyanathan; Inna Serganova; Ronald G Blasberg; Jason S Lewis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-31       Impact factor: 9.236

3.  Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter.

Authors:  T Pacholczyk; R D Blakely; S G Amara
Journal:  Nature       Date:  1991-03-28       Impact factor: 49.962

4.  Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.

Authors:  Julia A Messina; Su-Chun Cheng; Benjamin L Franc; Martin Charron; Barry Shulkin; Bao To; John M Maris; Gregory Yanik; Randall A Hawkins; Katherine K Matthay
Journal:  Pediatr Blood Cancer       Date:  2006-12       Impact factor: 3.167

5.  Potential and practical adrenomedullary PET radiopharmaceuticals as an alternative to m-iodobenzylguanidine: m-(omega-[18F]fluoroalkyl)benzylguanidines.

Authors:  Byung Chul Lee; Jin-Young Paik; Dae Yoon Chi; Kyung-Han Lee; Yearn Seong Choe
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

Review 6.  The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.

Authors:  V Rufini; B Shulkin
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-12       Impact factor: 2.346

7.  Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors.

Authors:  Martin Anlauf; Rolf Eissele; Martin K-H Schäfer; Lee E Eiden; Rudolf Arnold; Ursula Pauser; Günter Klöppel; Eberhard Weihe
Journal:  J Histochem Cytochem       Date:  2003-08       Impact factor: 2.479

8.  (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.

Authors:  G Vaidyanathan; D J Affleck; M R Zalutsky
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

9.  Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.

Authors:  Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Ivica Lazúrová; Karen T Adams; Shiromi Perera; Karel Pacak
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

10.  MIBG detection of hepatic neuroblastoma: correlation with CT, US and surgical findings.

Authors:  D A Dessner; M A DiPietro; B L Shulkin
Journal:  Pediatr Radiol       Date:  1993
View more
  18 in total

1.  A practical, automated synthesis of meta-[(18)F]fluorobenzylguanidine for clinical use.

Authors:  Bao Hu; Amy L Vāvere; Kiel D Neumann; Barry L Shulkin; Stephen G DiMagno; Scott E Snyder
Journal:  ACS Chem Neurosci       Date:  2015-09-11       Impact factor: 4.418

2.  Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Authors:  Neeta Pandit-Taskar; Pat Zanzonico; Kevin D Staton; Jorge A Carrasquillo; Diane Reidy-Lagunes; Serge Lyashchenko; Eva Burnazi; Hanwen Zhang; Jason S Lewis; Ronald Blasberg; Steven M Larson; Wolfgang A Weber; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-07-13       Impact factor: 10.057

3.  Guidelines on nuclear medicine imaging in neuroblastoma.

Authors:  Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10       Impact factor: 9.236

4.  Chemical Delivery System of MIBG to the Central Nervous System: Synthesis, 11C-Radiosynthesis, and in Vivo Evaluation.

Authors:  Fabienne Gourand; Delphine Patin; Axelle Henry; Méziane Ibazizène; Martine Dhilly; Fabien Fillesoye; Olivier Tirel; Mihaela-Liliana Tintas; Cyril Papamicaël; Vincent Levacher; Louisa Barré
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

5.  Comparative Analysis of T Cell Imaging with Human Nuclear Reporter Genes.

Authors:  Maxim A Moroz; Hanwen Zhang; Jason Lee; Ekaterina Moroz; Juan Zurita; Larissa Shenker; Inna Serganova; Ronald Blasberg; Vladimir Ponomarev
Journal:  J Nucl Med       Date:  2015-05-29       Impact factor: 10.057

6.  Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Eftychia Koumarianou; Jaeyeon Choi; Marc Hens; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2015-04-20       Impact factor: 2.408

Review 7.  PET/MRI in Pediatric Neuroimaging: Primer for Clinical Practice.

Authors:  C Pedersen; M Aboian; J E McConathy; H Daldrup-Link; A M Franceschi
Journal:  AJNR Am J Neuroradiol       Date:  2022-05-05       Impact factor: 4.966

8.  Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.

Authors:  Hanwen Zhang; Pooja Desai; Yusuke Koike; Jacob Houghton; Sean Carlin; Nidhi Tandon; Karim Touijer; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2016-08-11       Impact factor: 10.057

Review 9.  Contemporary approaches for imaging skeletal metastasis.

Authors:  David Ulmert; Lilja Solnes; Daniel Lj Thorek
Journal:  Bone Res       Date:  2015-07-14       Impact factor: 13.567

10.  Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma.

Authors:  Yen-Lin Liu; Meng-Yao Lu; Hsiu-Hao Chang; Ching-Chu Lu; Dong-Tsamn Lin; Shiann-Tarng Jou; Yung-Li Yang; Ya-Ling Lee; Shiu-Feng Huang; Yung-Ming Jeng; Hsinyu Lee; James S Miser; Kai-Hsin Lin; Yung-Feng Liao; Wen-Ming Hsu; Kai-Yuan Tzen
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.